MonoSolRx LLC Developing Migraine Product for Treatment of Pain and Nausea in a Single Dose

Published: Sep 13, 2012

WARREN, N.J., Sept. 13, 2012 (GLOBE NEWSWIRE) -- MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm® drug delivery technology, today announced that it is developing a new drug product for the treatment of migraines. The migraine treatment drug candidate, MSRX-202, utilizes MonoSol's PharmFilm® technology in a combination product that includes rizatriptan for the treatment of migraine pain and ondansetron for the treatment of nausea.

Back to news